Sharad K. Sharma

Sharad K. Sharma

Internal Medicine

200 Lothrop Street, UPMC Presbyterian G 100
Pittsburgh, PA 15213

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Advancing Nursing Cognitive Capacity Through Generative AI and Immersive VR as a Structural Intervention for Burnout and Administrative Burden.

Advancing Nursing Cognitive Capacity Through Generative AI and Immersive VR as a Structural Intervention for Burnout and Administrative Burden.

Journal: Nursing administration quarterly

Published: August 27, 2026

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A Randomized Clinical Trial.

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A Randomized Clinical Trial.

Journal: JAMA network open

Published: August 27, 2026

A Randomized Controlled Trial: Evaluating the Sleep, Cancer and Rest (SleepCaRe) Trial to Improve Health-Related Quality of Life in Women Undergoing Chemotherapy for Breast Cancer.

A Randomized Controlled Trial: Evaluating the Sleep, Cancer and Rest (SleepCaRe) Trial to Improve Health-Related Quality of Life in Women Undergoing Chemotherapy for Breast Cancer.

Journal: Psycho-oncology

Published: November 24, 2025

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.

Journal: European urology oncology

Published: November 19, 2025

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.

WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.

Journal: European urology oncology

Published: November 19, 2025

Discovery of MK-2118, a Small-Molecule Agonist of STING.

Discovery of MK-2118, a Small-Molecule Agonist of STING.

Journal: ACS medicinal chemistry letters

Published: September 11, 2025

Exploring potential predictors of low muscle mass and muscle loss in adults with cancer: A scoping review.

Exploring potential predictors of low muscle mass and muscle loss in adults with cancer: A scoping review.

Journal: Clinical nutrition (Edinburgh, Scotland)

Published: August 28, 2025

Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology.

Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology.

Journal: Clinical pharmacology and therapeutics

Published: February 29, 2024

Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.

Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.

Journal: JAMA oncology

Published: September 21, 2023

Telehealth in oncology: a cost analysis to evaluate the financial impact of implementing regional trial hubs within a phase 3 cancer clinical trial.

Telehealth in oncology: a cost analysis to evaluate the financial impact of implementing regional trial hubs within a phase 3 cancer clinical trial.

Journal: Internal medicine journal

Published: July 02, 2023

Systemically Administered Anti-uPAR Antibody Plasma and Lung ELF Pharmacokinetics Characterized by Minimal Lung PBPK Model.

Systemically Administered Anti-uPAR Antibody Plasma and Lung ELF Pharmacokinetics Characterized by Minimal Lung PBPK Model.

Journal: AAPS PharmSciTech

Published: May 18, 2023

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.

Journal: Journal for immunotherapy of cancer

Published: July 17, 2022

Showing 1-12 of 38

Last Updated: 09/26/2026